C4 Therapeutics

News

Roche places a $1bn bet on C4T degrader-antibody conjugates

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

News

FDA starts review of BMS's 'celmod' for multiple myeloma

Bristol Myers Squibb could be months away from bringing the first 'celmod' to market, as the FDA starts a review of iberdomide for multiple myeloma.

News

Pair of deals boosts Biogen’s early-stage CNS pipeline

Biogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates for Alzheimer’s, multiple sclerosis and other neurological diseases.

Roche places a $1bn bet on C4T degrader-antibody conjugates

FDA starts review of BMS's 'celmod' for multiple myeloma

Pair of deals boosts Biogen’s early-stage CNS pipeline

FDA clears Viridian's Tepezza rival for thyroid eye disease

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks